Samarium Sm 153 Lexidronam Injection
» Samarium Sm 153 Lexidronam Injection is a sterile aqueous solution suitable for intravenous injection that contains 153Sm in the form of a complex with ethylenediaminetetramethylenephosphonic acid (EDTMP). It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of 153Sm expressed in megabecquerels per mL (or in millicuries per mL) at the date and time indicated in the labeling. Not less than 99 percent of the Sm-153 is complexed by EDTMP. It contains no antimicrobial agents.
Packaging and storage—
Preserve in adequately shielded single-dose containers in a freezer.
Labeling—
Label it to include the following, in addition to the information specified for Labeling under Injections 
1
: the time and date of calibration; the amount of 153Sm complexed with EDTMP expressed as total megabecquerels (or millicuries) and the concentration as megabecquerels per mL (or millicuries per mL) at the time of calibration; the expiration date and time; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of 153Sm is 46.3 hours. The labeling indicates that it should not be diluted or mixed with other solutions, that it is to be thawed at room temperature before administration, and that it is to be used within 8 hours of thawing.
1: the time and date of calibration; the amount of 153Sm complexed with EDTMP expressed as total megabecquerels (or millicuries) and the concentration as megabecquerels per mL (or millicuries per mL) at the time of calibration; the expiration date and time; and the statement “Caution—Radioactive Material.” The labeling indicates that in making dosage calculations, correction is to be made for radioactive decay, and also indicates that the radioactive half-life of 153Sm is 46.3 hours. The labeling indicates that it should not be diluted or mixed with other solutions, that it is to be thawed at room temperature before administration, and that it is to be used within 8 hours of thawing.
Radionuclide identification 821—
Samarium-153 decays by beta emission to stable Europium 153 as follows: 640 keV (30%), 710 keV (50%), and 810 keV (20%). The average emission energy is 233 keV. Its gamma-ray spectrum is identical to that of a specimen of known purity of 153Sm that exhibits major photopeaks having energies of 70 keV and 103 keV.
821—
Samarium-153 decays by beta emission to stable Europium 153 as follows: 640 keV (30%), 710 keV (50%), and 810 keV (20%). The average emission energy is 233 keV. Its gamma-ray spectrum is identical to that of a specimen of known purity of 153Sm that exhibits major photopeaks having energies of 70 keV and 103 keV.
Bacterial endotoxins 85—
The limit of endotoxin content is not more than 175/V USP Endotoxin Unit per mL of Injection, in which V is the maximum recommended total dose, in mL, at the expiration time.
85—
The limit of endotoxin content is not more than 175/V USP Endotoxin Unit per mL of Injection, in which V is the maximum recommended total dose, in mL, at the expiration time.
pH 791:
between 7.0 and 8.5.
791:
between 7.0 and 8.5.
Radionuclidic purity 821—
Using a gamma ray spectrophotometer, determine the radionuclidic purity of the Injection: not less than 99.8% of the total radioactivity is present as Sm 153 at the time of expiry. The Europium 154 radioactivity is not more than 3.44 kBq per 37 MBq of Samarium 153 (or 0.0093% of total Samarium 153 at expiry). The sum of all other radionuclidic impurities is less than or equal to 0.1907% of the total Sm 153 at expiry.
821—
Using a gamma ray spectrophotometer, determine the radionuclidic purity of the Injection: not less than 99.8% of the total radioactivity is present as Sm 153 at the time of expiry. The Europium 154 radioactivity is not more than 3.44 kBq per 37 MBq of Samarium 153 (or 0.0093% of total Samarium 153 at expiry). The sum of all other radionuclidic impurities is less than or equal to 0.1907% of the total Sm 153 at expiry.
Radiochemical purity 821—
821—
Mobile phase—
Transfer 8.0 g of sodium chloride, 0.2 g of monobasic potassium phosphate, 1.15 g of dibasic sodium phosphate, and 0.2 g of potassium chloride to a 1-liter volumetric flask, dilute with distilled water to volume, and mix. Make adjustments if necessary (see System Suitability under Chromatography 621).
621).
Chromatographic system
(see Chromatography 621)—A 10-mm × 40-mm glass chromatographic column is packed using gravity flow with a strong cation-exchange resin* (prepared by mixing 5 g of resin with 25 mL of water in a suitable beaker) to a final resin volume of 0.5 mL.
621)—A 10-mm × 40-mm glass chromatographic column is packed using gravity flow with a strong cation-exchange resin* (prepared by mixing 5 g of resin with 25 mL of water in a suitable beaker) to a final resin volume of 0.5 mL.
Procedure—
Transfer the packed column to an ion-chamber dose counter to determine the background count for Sm 153. Apply about 10 µL of the Injection onto the column and place it in the ion-chamber counter, and record the total radioactivity. Elute the complexed radioactivity using about 20 mL of Mobile phase, and record the radioactivity retained on the column. Subtract the background radioactivity from all measured radioactivity values. Calculate the percentage of complexed radioactivity in the portion of Injection taken by the formula:
100(T 
S / 0.95) / T
in which T is the total amount of radioactivity; S is the quantity of free Sm-153 retained on the column; and 0.95 is the correction factor (5% of the uncomplexed Sm 153 passes through the column and into the Injection): not less than 99% of the Sm-153 is complexed by EDTMP.
S / 0.95) / T
Other requirements—
It meets the requirements under Injections 1, except that it is not subject to the recommendation on Volume in Container.
1, except that it is not subject to the recommendation on Volume in Container.
Assay for radioactivity 821—
Using a suitable counting assembly (see Gamma-Emitting Radionuclides under the Assay), determine the radioactivity in MBq (or mCi) per mL of Injection by use of a calibrated system: the activity is within ±10% of the labeled amount at the time of calibration.
821—
Using a suitable counting assembly (see Gamma-Emitting Radionuclides under the Assay), determine the radioactivity in MBq (or mCi) per mL of Injection by use of a calibrated system: the activity is within ±10% of the labeled amount at the time of calibration.
*
Sephadex-CM C-25 brand of ion exchange resin is available from Aldrich Chemical (No. 27, 124-1).
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
| Monograph | Ian DeVeau, Ph.D.
Director, Veterinary Drugs and Radiopharmaceuticals 1-301-816-8178 |
(RMI05) Radiopharmaceuticals and Medical Imaging Agents 05 |
| Reference Standards | Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org |
|
| 85 |
Radhakrishna S Tirumalai, Ph.D.
Senior Scientist 1-301-816-8339 |
(MSA05) Microbiology and Sterility Assurance |
USP32–NF27 Page 3536